• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    6/16/25 4:32:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email
    bdx-20250616
    0000010795false00000107952025-06-162025-06-160000010795us-gaap:CommonStockMemberexch:XNYS2025-06-162025-06-160000010795bdx:Notes1.900dueDecember152026Memberexch:XNYS2025-06-162025-06-160000010795bdx:Notes1.208dueJune42026Memberexch:XNYS2025-06-162025-06-160000010795bdx:Notes1213DueFebruary122036Memberexch:XNYS2025-06-162025-06-160000010795bdx:Notes0034DueAugust132025Memberexch:XNYS2025-06-162025-06-160000010795bdx:Notes3.519DueFebruary82031Memberexch:XNYS2025-06-162025-06-160000010795bdx:Notes3.828DueJune72032Memberexch:XNYS2025-06-162025-06-16

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K
    CURRENT REPORT PURSUANT TO
    SECTION 13 OR 15(D) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported) June 16, 2025
    BECTON, DICKINSON AND COMPANY
    (Exact Name of Registrant as Specified in Its Charter)
    New Jersey
    (State or Other Jurisdiction of Incorporation)
    001-4802 22-0760120
    (Commission File Number) (IRS Employer Identification No.)
      
    1 Becton Drive, Franklin Lakes,
    New Jersey
     07417-1880
    (Address of Principal Executive Offices) (Zip Code)
    (201) 
    847-6800
     (Registrant’s Telephone Number, Including Area Code)
    N/A
    (Former Name or Former Address, if Changed Since Last Report)
     
    Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:



    Title of Each ClassTrading Symbol
    Name of each exchange on
    which registered
    Common stock, par value $1.00BDXNew York Stock Exchange
    1.900% Notes due December 15, 2026BDX26New York Stock Exchange
    1.208% Notes due June 4, 2026BDX/26ANew York Stock Exchange
    1.213% Notes due February 12, 2036BDX/36New York Stock Exchange
    0.034% Notes due August 13, 2025BDX25ANew York Stock Exchange
    3.519% Notes due February 8, 2031BDX31New York Stock Exchange
    3.828% Notes due June 7, 2032BDX32ANew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company 
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐





    ITEM 7.01. REGULATION FD DISCLOSURE.

    Becton, Dickinson and Company furnishes as Exhibit 99.1 to this Current Report on Form 8-K a copy of the Notice of Pendency and Proposed Settlement of Stockholder Action (the “Notice”) of the consolidated stockholder derivative action captioned In re Becton, Dickinson and Company Stockholder Derivative Litigation, No. 2:20-cv-15474-SRC-CLW (D.N.J.) and the substantially similar stockholder derivative action captioned Lotz v. Burzik, et al., Docket No. BER-C-00174-24 (N.J. Sup. Ct. – Bergen Cnty.). Information concerning the terms of the proposed settlement and the related hearing can be found in the Notice.

    The information included or incorporated in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.






    ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS.
    Exhibit 99.1     Notice of Pendency of Proposed Settlement of Stockholder Action.

    Exhibit 104    Cover Page Interactive Data File (formatted as Inline XBRL document and contained in Exhibit 101).



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    BECTON, DICKINSON AND COMPANY
    (Registrant)
    By:/s/ Stephanie M. Kelly
     Stephanie M. Kelly
     Chief Securities and Governance Counsel, Corporate Secretary
    Date: June 16, 2025

    Get the next $BDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    5/1/2025Outperform → Mkt Perform
    William Blair
    10/1/2024$255.00 → $275.00Neutral → Buy
    Citigroup
    More analyst ratings